Literature DB >> 3282079

Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

R B Belshe1, M H Smith, C B Hall, R Betts, A J Hay.   

Abstract

The emergence of influenza A viruses which had acquired resistance to rimantadine during a clinical trial (C. B. Hall, R. Dolin, C. L. Gala, D. M. Markovitz, Y. Q. Zhang, P. H. Madore, F. A. Disney, W. B. Talpey, J. L. Green, A. B. Francis, and M. E. Pichichero, Pediatrics 80:275-282, 1987) provided the opportunity to determine the genetic basis of this phenomenon. Analysis of reassortant viruses generated with a resistant clinical isolate (H3N2) and the susceptible influenza A/Singapore/57 (H2N2) virus indicated that RNA segment 7 coding for matrix and M2 proteins conferred the resistant phenotype. Resistant viruses isolated from seven patients each contained a single change in the nucleotide sequence coding for the M2 protein which resulted in substitutions in amino acid 30 (two viruses) or 31 (five viruses) in the transmembrane domain of the molecule. These changes occurred in locations identified in influenza viruses selected for resistance to amantadine in tissue culture and indicate a common mechanism of action of the two compounds in cell culture and during chemotherapeutic use.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282079      PMCID: PMC253174     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man.

Authors:  W L Wingfield; D Pollack; R R Grunert
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

2.  Treatment of influenza. The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak.

Authors:  S Rabinovich; J T Baldini; R Bannister
Journal:  Am J Med Sci       Date:  1969-05       Impact factor: 2.378

3.  In vivo selection of an influenza A2 strain resistant to amantadine.

Authors:  J S Oxford; I S Logan; C W Potter
Journal:  Nature       Date:  1970-04-04       Impact factor: 49.962

4.  Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates.

Authors:  R M Pemberton; R Jennings; C W Potter; J S Oxford
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

5.  Molecular basis of resistance of influenza A viruses to amantadine.

Authors:  A J Hay; M C Zambon; A J Wolstenholme; J J Skehel; M H Smith
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

6.  Children with influenza A infection: treatment with rimantadine.

Authors:  C B Hall; R Dolin; C L Gala; D M Markovitz; Y Q Zhang; P H Madore; F A Disney; W B Talpey; J L Green; A B Francis
Journal:  Pediatrics       Date:  1987-08       Impact factor: 7.124

7.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

8.  A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children.

Authors:  J Thompson; W Fleet; E Lawrence; E Pierce; L Morris; P Wright
Journal:  J Med Virol       Date:  1987-03       Impact factor: 2.327

9.  Chemotherapy and vaccination: a possible strategy for the control of highly virulent influenza virus.

Authors:  R G Webster; Y Kawaoka; W J Bean; C W Beard; M Brugh
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

10.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  76 in total

1.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Amantadine for influenza A.

Authors:  K G Nicholson; M J Wiselka
Journal:  BMJ       Date:  1991-02-23

3.  Low-Fidelity Assembly of Influenza A Virus Promotes Escape from Host Cells.

Authors:  Michael D Vahey; Daniel A Fletcher
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

4.  Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Qingmei Weng; Ashley Brown; Robert Kulawy; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

5.  Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus.

Authors:  Ekta Khurana; Matteo Dal Peraro; Russell DeVane; Satyavani Vemparala; William F DeGrado; Michael L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

6.  Evolution of an avian H5N1 influenza A virus escape mutant.

Authors:  Kamel M A Hassanin; Ahmed S Abdel-Moneim
Journal:  World J Virol       Date:  2013-11-12

7.  1, 8-Cineol Protect Against Influenza-Virus-Induced Pneumonia in Mice.

Authors:  Yun Li; Yanni Lai; Yao Wang; Ni Liu; Fengxue Zhang; Peiping Xu
Journal:  Inflammation       Date:  2016-08       Impact factor: 4.092

Review 8.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

9.  Distribution and dynamics of adamantanes in a lipid bilayer.

Authors:  Chee Foong Chew; Andrew Guy; Philip C Biggin
Journal:  Biophys J       Date:  2008-10-03       Impact factor: 4.033

Review 10.  Pandemic and seasonal influenza: therapeutic challenges.

Authors:  Matthew J Memoli; David M Morens; Jeffery K Taubenberger
Journal:  Drug Discov Today       Date:  2008-05-15       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.